文献速递产科母胎医学

前列腺素用于胎儿生长受限妊娠引产

Prostaglandins for induction in pregnancies with fetal growth restriction.
PubMed 文献 · Am J Obstet Gynecol MFM · 2021-11-20

基于安全分娩联盟数据库的倾向评分二次分析,纳入足月、单胎、非畸形胎儿生长受限妊娠且无剖宫产史者。前列腺素引产组新生儿不良结局复合率与无前列腺素组无差异,但剖宫产率及因胎心监护异常剖宫产率更高。

要点

  • 前列腺素引产组新生儿不良结局复合率10.4% vs 非前列腺素组6.7%,调整OR 1.39(0.64-3.03),无差异。
  • 前列腺素组剖宫产率25.5% vs 非前列腺素组14.8%,调整OR 1.80(1.07-3.02)。
  • 因胎心监护异常剖宫产率前列腺素组16.0% vs 非前列腺素组8.7%,调整OR 2.37(1.28-4.41)。

核心结论

  • 胎儿生长受限妊娠引产时使用前列腺素与非前列腺素方法相比,新生儿不良结局复合率无差异,但剖宫产率及因胎心监护异常剖宫产率更高。

研究设计与样本

  • 基于安全分娩联盟数据库的倾向评分二次分析。
  • 纳入足月、单胎、非畸形胎儿生长受限妊娠(估计胎儿体重小于胎龄第10百分位),排除既往剖宫产。
  • 共756例引产(0.3%),前列腺素组212例(28%),其中前列腺素E1 108例、前列腺素E2 94例;非前列腺素组553例(72%),包括缩宫素348例(63%)、人工破膜211例(38%)和/或机械扩张9例(1%)。

主要发现

  • 新生儿不良结局复合率前列腺素组10.4% vs 非前列腺素组6.7%,调整OR 1.39(95%CI 0.64-3.03)。
  • 剖宫产率前列腺素组25.5% vs 非前列腺素组14.8%,调整OR 1.80(95%CI 1.07-3.02)。
  • 因胎心监护异常剖宫产率前列腺素组16.0% vs 非前列腺素组8.7%,调整OR 2.37(95%CI 1.28-4.41)。
  • 分别分析前列腺素E1和E2时,两者与非前列腺素对照相比,新生儿不良结局复合率和剖宫产率均有相似升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The data on safety of prostaglandin agents for induction of pregnancies with fetal growth restriction is limited. OBJECTIVE: To compare the rates of adverse outcomes among pregnancies with fetal growth restriction undergoing induction of labor with and without prostaglandins STUDY DESIGN: We performed a propensity-score-based secondary analysis of the Consortium on Safe Labor database. We included term, singleton, and nonanomalous pregnancies with fetal growth restriction (estimated fetal weight <10th percentile for gestational age). We excluded previous cesarean deliveries. The primary exposure was induction using prostaglandins (prostaglandin E1 or prostaglandin E2) compared with other methods. The primary outcome was a composite of adverse neonatal outcomes. The secondary outcomes included all cesarean deliveries and cesarean deliveries for nonreassuring fetal heart tracings. A subgroup analysis comparing the type of prostaglandin was planned a priori. The results are expressed as adjusted odds ratios with 95% confidence intervals. RESULTS: Of 756 (0.3%) inductions, 212 (28%) used prostaglandins (108 prostaglandin E1, 94 prostaglandin E2), and 553 (72%) used nonprostaglandin methods, including oxytocin (348, 63%), amniotomy (211, 38%), and/or mechanical dilation (9, 1%). There were no differences in the composite of adverse neonatal outcomes between the prostaglandin (10.4%) and the nonprostaglandin group (6.7%), adjusted odds ratio, 1.39 (0.64-3.03). The rate of cesarean delivery was higher in the inductions that received prostaglandins than those that did not (25.5% vs 14.8%, adjusted odds ratio, 1.80; 1.07-3.02). The rate of cesarean delivery for nonreassuring fetal heart tracings was higher for those that received prostaglandins than those that did not (16.0% vs 8.7%, adjusted odds ratio, 2.37; 1.28-4.41). When prostaglandin E1 and prostaglandin E2 were examined independently, there were similar increases in the composite of adverse neonatal outcomes and cesarean delivery rates for both prostaglandin E1 and prostaglandin E2 compared with nonprostaglandin controls. CONCLUSION: There were no differences in the composite of adverse neonatal outcomes when prostaglandins were used for induction in pregnancies with fetal growth restriction compared with other methods. However, there was a higher rate of cesarean delivery and cesarean delivery indicated for nonreassuring fetal heart tracings when prostaglandins (both prostaglandin E1 and prostaglandin E2) were used, compared with nonprostaglandin methods.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Al-Hafez L, Bicocca MJ, Chauhan SP, et al. Prostaglandins for induction in pregnancies with fetal growth restriction. Am J Obstet Gynecol MFM. 2021. PMID: 34813974. doi:10.1016/j.ajogmf.2021.100538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。